

100 Days of Results: President Trump's American Patients First Blueprint

Lower Out-of-Pocket Costs

- ✓ Put industry on notice that “gag clauses” causing seniors to pay more at the pharmacy are unacceptable
- ✓ Supported passage out of committee of legislation to ban private-sector gag clauses
- ✓ Proposed to decrease the price paid by taxpayers and patients for certain new drugs in Medicare
- ✓ Clarified tools that Part D plans have to help patients access low-cost generics rather than more expensive, branded competitors
- ✓ Proposed lower payments for certain discounted drugs, meaning lower out-of-pocket costs for seniors at more sites of care
- ✓ Announced that the average Part D premium would drop for the second year in a row

Increased Competition

- ✓ Approved, through FDA, a record number of generic drugs in July
- ✓ Approved first product designated as a “competitive generic therapy” under a pathway created to expedite development and review of products that lack competition
- ✓ Launched a working group on how safe, short-term importation of certain medically necessary drugs could address price spikes
- ✓ Announced an FDA Biosimilar Action Plan to spur competition among expensive biologic drugs
- ✓ Took action to stop drug companies from gaming certain FDA safety programs to block cheaper competition

“The President’s blueprint for lower drug prices is working, drug prices are coming down, and American patients are going to see the savings in their pocketbook.”

— SECRETARY ALEX AZAR

Better Negotiation

- ✓ Gave Medicare Advantage new negotiation tools to drive down prices for patients
- ✓ Provided new guidance to help insurers and drug companies reach better deals for patients
- ✓ Solicited comment on ways to use private-sector competitive acquisition for Medicare Part B drugs
- ✓ Approved first-of-its-kind waiver for a state to negotiate pricing contracts with drug makers to secure more value

Incentives for Lower List Prices

- ✓ Supporting the introduction of legislation to undo the Obamacare giveaway to drug companies on Medicaid rebates
- ✓ Began publishing individual drug price increases on CMS’s drug dashboard
- ✓ Worked with drug companies to secure historically unprecedented rollbacks or cuts in list prices

U.S. Department of Health and Human Services
**100 Days of Results: President Trump's
American Patients First Blueprint**

Drug company responses:

2

Lowering Prices or
Rolled Back Increases

13

Committed to Price
Freezes for Rest of 2018

4

Canceled Planned
Price Increases


Since the blueprint release, drug companies have implemented:

60%

fewer brand-drug **price
increases** than the same
period in 2017

54%

more generic and brand-drug
price decreases than the same
period in 2017



20 million

Seniors on Medicare
Advantage plans that will now
have new tools to negotiate



**Record-Breaking
126 generics**

Approved in July



3,028

Comments on the
Blueprint